Transcode Therapeutics
TransCode Therapeutics is a Boston-based biotechnology company focused on oncology, aiming to deliver a cancer-free future through the intelligent design and efficient delivery of targeted therapeutics. Their platform, TTX, overcomes delivery challenges in cancer treatment, enabling targeting of previously undruggable targets and addressing tumor resistance. They focus on metastatic disease, with a pipeline of therapeutic candidates including TTX-MC138, targeting microRNA-10b, which is a master regulator of metastasis across multiple cancer types. The company is committed to revolutionizing cancer treatment by applying their TTX platform to develop therapies that improve patient outcomes and enable long-term survival.
Industries
Nr. of Employees
small (1-50)
Transcode Therapeutics
Newton, Massachusetts, United States, North America
Products
miRNA-10b inhibitor delivered by targeted nanoparticle (lead therapeutic candidate)
An oligonucleotide-based inhibitor of miRNA-10b formulated on an imaging-capable iron-oxide nanoparticle delivery system intended to target metastatic tumor cells; evaluated in murine models for breast and pancreatic cancer with reported regression outcomes in preclinical studies.
siRNA-based PD-L1 silencing therapeutic (siPDL1)
siRNA payloads targeting PD-L1 mRNA formulated for tumor-resident cell delivery to reduce PD-L1 expression rather than block protein function, with preclinical activity in pancreatic cancer models and orphan designation referenced.
RIG-I agonist approach (tumor-targeted innate immunity agonist)
Delivery of tumor-specific RNA payloads to engage RIG-I signaling inside tumor cells to induce tumor cell death and activate innate/adaptive immune responses.
Radiolabeled nanoparticle imaging and radiotherapeutic constructs (e.g., 64Cu-labeled)
Nanoparticle constructs labeled with PET isotopes for microdosing biodistribution studies and for potential use as localized radiotherapeutic delivery vehicles.
mRNA-based cancer vaccine delivery
mRNA payload delivery via nanoparticle platform intended to generate cytotoxic immune responses against tumor cells.
miRNA detection biomarker assay for blood/serum
A fluorescence-based assay intended to quantify microRNA expression in blood samples for early detection, staging, and monitoring therapeutic response (development-stage, not FDA-approved).
miRNA-10b inhibitor delivered by targeted nanoparticle (lead therapeutic candidate)
An oligonucleotide-based inhibitor of miRNA-10b formulated on an imaging-capable iron-oxide nanoparticle delivery system intended to target metastatic tumor cells; evaluated in murine models for breast and pancreatic cancer with reported regression outcomes in preclinical studies.
siRNA-based PD-L1 silencing therapeutic (siPDL1)
siRNA payloads targeting PD-L1 mRNA formulated for tumor-resident cell delivery to reduce PD-L1 expression rather than block protein function, with preclinical activity in pancreatic cancer models and orphan designation referenced.
RIG-I agonist approach (tumor-targeted innate immunity agonist)
Delivery of tumor-specific RNA payloads to engage RIG-I signaling inside tumor cells to induce tumor cell death and activate innate/adaptive immune responses.
Radiolabeled nanoparticle imaging and radiotherapeutic constructs (e.g., 64Cu-labeled)
Nanoparticle constructs labeled with PET isotopes for microdosing biodistribution studies and for potential use as localized radiotherapeutic delivery vehicles.
mRNA-based cancer vaccine delivery
mRNA payload delivery via nanoparticle platform intended to generate cytotoxic immune responses against tumor cells.
miRNA detection biomarker assay for blood/serum
A fluorescence-based assay intended to quantify microRNA expression in blood samples for early detection, staging, and monitoring therapeutic response (development-stage, not FDA-approved).
Services
Partnerships and licensing for therapeutic and diagnostic development
Collaboration, option and licensing arrangements with academic and commercial partners to co-develop, license, or commercialize nanoparticle-delivered therapeutics and diagnostics.
Early-phase clinical development and trial sponsorship
Sponsorship and planning of early human studies (Phase 0 and planned Phase I/II) for nanoparticle-delivered RNA therapeutics targeting metastatic cancers.
Partnerships and licensing for therapeutic and diagnostic development
Collaboration, option and licensing arrangements with academic and commercial partners to co-develop, license, or commercialize nanoparticle-delivered therapeutics and diagnostics.
Early-phase clinical development and trial sponsorship
Sponsorship and planning of early human studies (Phase 0 and planned Phase I/II) for nanoparticle-delivered RNA therapeutics targeting metastatic cancers.
Expertise Areas
- Targeted nanoparticle delivery for oncology
- RNA therapeutics (miRNA inhibitors, siRNA, mRNA)
- Preclinical oncology models and translational studies
- Theranostics and molecular imaging
Key Technologies
- Iron-oxide nanoparticle delivery
- Dextran surface crosslinking and amino-group functionalization
- Oligonucleotide therapeutics (antisense, siRNA, miRNA inhibitors)
- mRNA delivery for cancer vaccines